ATE467422T1 - Behandlung von aspergillus-infektionen mit thymosin alpha 1 - Google Patents

Behandlung von aspergillus-infektionen mit thymosin alpha 1

Info

Publication number
ATE467422T1
ATE467422T1 AT04749495T AT04749495T ATE467422T1 AT E467422 T1 ATE467422 T1 AT E467422T1 AT 04749495 T AT04749495 T AT 04749495T AT 04749495 T AT04749495 T AT 04749495T AT E467422 T1 ATE467422 T1 AT E467422T1
Authority
AT
Austria
Prior art keywords
thymosin alpha
treating
aspergillus infections
treating aspergillus
immuno
Prior art date
Application number
AT04749495T
Other languages
English (en)
Inventor
Guido Rasi
Enrico Garaci
Francesco Bistoni
Luigina Romani
Francesco Paolo Di
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE467422T1 publication Critical patent/ATE467422T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04749495T 2003-03-28 2004-03-29 Behandlung von aspergillus-infektionen mit thymosin alpha 1 ATE467422T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45791103P 2003-03-28 2003-03-28
PCT/US2004/009550 WO2004087067A2 (en) 2003-03-28 2004-03-29 Treatment of aspergillus infections with thymosin alpha 1

Publications (1)

Publication Number Publication Date
ATE467422T1 true ATE467422T1 (de) 2010-05-15

Family

ID=42828702

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749495T ATE467422T1 (de) 2003-03-28 2004-03-29 Behandlung von aspergillus-infektionen mit thymosin alpha 1

Country Status (17)

Country Link
US (2) US8207294B2 (de)
EP (1) EP1613340B1 (de)
JP (1) JP4629033B2 (de)
KR (1) KR101089145B1 (de)
AT (1) ATE467422T1 (de)
AU (1) AU2004226403B2 (de)
BR (1) BRPI0408892A (de)
CA (1) CA2520400C (de)
DK (1) DK1613340T3 (de)
EA (1) EA008037B1 (de)
IL (1) IL171118A (de)
MX (1) MXPA05010391A (de)
NO (1) NO329997B1 (de)
NZ (1) NZ542900A (de)
PL (1) PL1613340T3 (de)
UA (1) UA80870C2 (de)
WO (1) WO2004087067A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0408892A (pt) 2003-03-28 2006-04-11 Sciclone Pharmaceuticals Inc uso de timosina alfa 1 para tratar as infecções por arpergillus
CN101072582B (zh) * 2004-12-06 2012-06-27 赛生制药有限公司 作为癌症疫苗佐剂的α胸腺肽
AU2007253527B2 (en) * 2006-05-19 2012-04-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1 for the treatment of immunological diseases
ITRM20060583A1 (it) * 2006-10-27 2008-04-28 Francesco Bistoni Uso della timosina alfa 1 per la preparazione di un medicamento per la prevenzione e la cura delle allergie
EP2675272A4 (de) * 2011-02-09 2015-03-11 Sciclone Pharmaceuticals Inc Thymosin-alpha-peptid zur prävention, linderung und behandlung von infektionen
ITUB20153714A1 (it) * 2015-09-18 2017-03-18 Luigina Romani Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica.
BR112017016205A2 (pt) * 2015-02-09 2018-03-27 Romani Luigina thymosin alpha 1 para uso no tratamento de fibrose cística

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002740A (en) * 1975-08-21 1977-01-11 Gideon Goldstein Tridecapeptide compositions and methods
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4612365A (en) * 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4374197A (en) * 1980-10-30 1983-02-15 Hoffmann-La Rocche Inc. Process for thymosin α1
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien
CN1058500C (zh) * 1993-02-03 2000-11-15 施塞克龙药品公司 胸腺素α-1衍生物
CN1072961C (zh) 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
TW252045B (de) * 1993-10-07 1995-07-21 Allan L Goldstein
RU2107692C1 (ru) * 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
WO1998035696A1 (en) * 1997-02-18 1998-08-20 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha 1 for the manufacture of a medicament for promoting stem cell development
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
BRPI0408892A (pt) 2003-03-28 2006-04-11 Sciclone Pharmaceuticals Inc uso de timosina alfa 1 para tratar as infecções por arpergillus

Also Published As

Publication number Publication date
US8389680B2 (en) 2013-03-05
NO20054912L (no) 2005-12-20
CA2520400A1 (en) 2004-10-14
JP4629033B2 (ja) 2011-02-09
KR101089145B1 (ko) 2011-12-02
PL1613340T3 (pl) 2010-10-29
US20120295840A1 (en) 2012-11-22
CA2520400C (en) 2013-02-19
NO329997B1 (no) 2011-02-07
US8207294B2 (en) 2012-06-26
EP1613340A4 (de) 2009-07-01
EP1613340A2 (de) 2006-01-11
UA80870C2 (en) 2007-11-12
MXPA05010391A (es) 2005-11-04
BRPI0408892A (pt) 2006-04-11
NO20054912D0 (no) 2005-10-24
WO2004087067A3 (en) 2004-12-29
AU2004226403B2 (en) 2008-12-04
JP2006521406A (ja) 2006-09-21
EA008037B1 (ru) 2007-02-27
EP1613340B1 (de) 2010-05-12
AU2004226403A1 (en) 2004-10-14
NZ542900A (en) 2007-06-29
WO2004087067A2 (en) 2004-10-14
EA200501414A1 (ru) 2006-04-28
IL171118A (en) 2011-10-31
US20070129292A1 (en) 2007-06-07
DK1613340T3 (da) 2010-08-30
KR20050114264A (ko) 2005-12-05

Similar Documents

Publication Publication Date Title
DE60026561D1 (de) Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
ATE404240T1 (de) Vorrichtung zur behandlung von biologischen geweben mittels elektrizität oder medikamenten
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
DE60328977D1 (de) System zur positionierung von implantierbaren medizinischen vorrichtungen in den koronarvenen
DE60119734D1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
DE60316338D1 (de) N-alkyl-4-methylenamino-3-hydroxy-2-pyridone verwendbar als antimikrobielle mittel
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
GB0518804D0 (en) Exudialysis tissue cleanser
EA200700965A1 (ru) Трегалоза и/или изомальтулоза в качестве носителя для сухой ароматической композиции
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
ATE531419T1 (de) Vorrichtung zur verabreichung von therapeutischen mitteln
ATE427116T1 (de) Behandlung von bakteriellen infektionen
ATE427127T1 (de) Bioaktive beschichtung fur medizinische vorrichtung mit keratin
DK1778833T3 (da) Fremgangsmåder til anvendelse af regenerative celler til at fremme sårheling
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
EA200501414A1 (ru) Лечение инфекций, вызываемых грибами p. aspergillus, с помощью тимозина альфа 1
BR0205439B1 (pt) método para concentração e recuperação de patógenos a partir de um fluido e circuito de fluido descartável para uso no mesmo.
ATE372986T1 (de) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridon s als antimikrobielle mittel
ATE372132T1 (de) Verfahren zum sterilisieren von gegenständen
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
NZ512850A (en) Treatment of papillomavirus infections
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1613340

Country of ref document: EP